Version 1
: Received: 28 December 2023 / Approved: 29 December 2023 / Online: 29 December 2023 (10:35:47 CET)
How to cite:
Bestari, M. B.; Joewono, I. R.; Syam, A. F. Early Biomarkers for Pancreatic Cancer: A Quest for Survival, Review on the Most Effective Approaches at Present. Preprints2023, 2023122276. https://doi.org/10.20944/preprints202312.2276.v1
Bestari, M. B.; Joewono, I. R.; Syam, A. F. Early Biomarkers for Pancreatic Cancer: A Quest for Survival, Review on the Most Effective Approaches at Present. Preprints 2023, 2023122276. https://doi.org/10.20944/preprints202312.2276.v1
Bestari, M. B.; Joewono, I. R.; Syam, A. F. Early Biomarkers for Pancreatic Cancer: A Quest for Survival, Review on the Most Effective Approaches at Present. Preprints2023, 2023122276. https://doi.org/10.20944/preprints202312.2276.v1
APA Style
Bestari, M. B., Joewono, I. R., & Syam, A. F. (2023). Early Biomarkers for Pancreatic Cancer: A Quest for Survival, Review on the Most Effective Approaches at Present. Preprints. https://doi.org/10.20944/preprints202312.2276.v1
Chicago/Turabian Style
Bestari, M. B., Ignatius Ronaldi Joewono and Ari Fahrial Syam. 2023 "Early Biomarkers for Pancreatic Cancer: A Quest for Survival, Review on the Most Effective Approaches at Present" Preprints. https://doi.org/10.20944/preprints202312.2276.v1
Abstract
Pancreatic cancer is the most lethal cancer, it has lowest 5-year survival rate among other types of cancers. More than half of pancreatic cancer are diagnosed at distant stage due to its insidious and non-specific symptoms. Surgery is the most effective treatment to date, but only 10-20% are resectable upon diagnosis. Currently, the only biomarker approved by the United States Food and Drug Administration (US-FDA) for pancreatic cancer is carbohydrate antigen 19-9 (CA19-9); however, it has limited use for early diagnosis. An increasing number of studies have a combination of biomarkers. Recently, the application for liquid biopsy has drawn a lot of attention, such as the use of microRNA (miRNA), circulating tumor DNA (ctDNA), and circulating tumor cells (CTC). Screening for pancreatic cancer is indicated for high-risk patients; studies of new diagnostic models combined with biomarkers for early detection also showed promising results to aid clinicians in deciding on whether to start screening. This review aims to summarize the progress on current biomarkers and new potential strategies for early detection of pancreatic cancer.
Keywords
pancreatic cancer; early biomarker; early diagnosis
Subject
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
